Keyphrases
Percutaneous Coronary Intervention
100%
Orsiro Stent
53%
Sirolimus
53%
Clinical Outcome
52%
Stent
49%
Anti-CD34 Antibody
49%
Dual Therapy
49%
Acute Coronary Syndrome
35%
Registry Study
34%
Confidence Interval
33%
Clinical Comparison
32%
Randomized Clinical
32%
Myocardial Infarction
32%
Chronic Total Occlusion
28%
Target Lesion Failure
28%
Target Lesion Revascularization
24%
Rate Ratio
23%
Randomized Trial
21%
Biodegradable Polymer Drug-eluting Stents
21%
Biodegradable Polymers
20%
Scandinavian
20%
Coronary Intervention
19%
Denmark
19%
Chronic Coronary Syndrome
18%
Revascularization
18%
Ultra-thin Strut
17%
Sirolimus-eluting Stent
16%
Biodegradable Polymer Biolimus-eluting Stents
16%
Pharmaceutical Treatment
16%
Nationwide Registry
16%
Line Assay
16%
ST-elevation Myocardial Infarction (STEMI)
16%
Elective Patients
16%
Elastin Gene
16%
Cutis Laxa
16%
Ticagrelor
16%
Percutaneous Intervention
16%
Occlusion Therapy
16%
Complex Arrhythmias
16%
P2Y12 Inhibitors
16%
Autosomal Dominant Cutis Laxa
16%
Acute Coronary Occlusion
16%
Pericardiocentesis
16%
Coronary Perforation
16%
Stepped-wedge Trial
16%
In-stent Restenosis
16%
All-cause Mortality
16%
Conservative Treatment
16%
Cardiac Death
15%
Prasugrel
14%
Medicine and Dentistry
Rapamycin
83%
Percutaneous Coronary Intervention
80%
Target Lesion
53%
Myocardial Infarction
46%
Acute Coronary Syndrome
43%
Target Lesion Revascularization
39%
Diabetes Mellitus
38%
Revascularization
35%
Umirolimus
34%
Chronic Total Occlusion
32%
Heart Death
32%
Stenosis
31%
Diabetes
28%
Heart Muscle Ischemia
21%
Coronary Angiography
20%
Heart Muscle Revascularization
19%
Patient with Diabetes
19%
All Cause Mortality
19%
Coronary Occlusion
16%
Primary Percutaneous Coronary Intervention
16%
Coronary Computed Tomography Angiography
16%
Conditioning
16%
Left Coronary Artery
16%
Autosomal Dominant Inheritance
16%
Randomized Controlled Trial
16%
Elastin
16%
Acute Heart Infarction
16%
Cardiovascular Disease
16%
Coronary Artery Perforation
16%
Pericardiocentesis
16%
In-Stent Restenosis
16%
Conservative Treatment
16%
Intention-to-Treat Analysis
14%
Arm
14%
Multidetector Computed Tomography
13%
Stent Thrombosis
12%
Heart Failure
10%
Drug-Eluting Stent
8%
Ischemic Heart Disease
8%
Alcohol Withdrawal Syndrome
8%
Coronary Artery Disease
7%
Randomized Clinical Trial
7%
Attributable Risk
7%
Patient Referral
6%
Noninferiority Trial
5%
ST Segment Elevation Myocardial Infarction
5%
Bleeding
5%
Endothelial Progenitor Cell
5%
Patient Population
5%
Hazard Ratio
5%
Pharmacology, Toxicology and Pharmaceutical Science
Rapamycin
100%
Heart Infarction
76%
CD34 Antibody
65%
Heart Death
39%
Acute Coronary Syndrome
38%
All Cause Mortality
36%
Umirolimus
34%
Diabetes Mellitus
32%
Chronic Total Occlusion
32%
Stent Thrombosis
28%
Coronary Artery Occlusion
16%
ST Segment Elevation Myocardial Infarction
16%
Ticagrelor
16%
Biological Marker
16%
Pharmacotherapy
16%
Heart Arrhythmia
16%
Stable Angina Pectoris
16%
In-Stent Restenosis
16%
Prasugrel
14%
Stenosis
14%
Creatine Kinase MB
13%
Clopidogrel
13%
Noninferiority Trial
9%
Efficacy Study
8%
Mortality Rate
8%
Randomized Clinical Trial
7%
Coronary Artery Disease
7%
Heart Failure
6%
Morinda citrifolia
5%
Major Adverse Cardiac Event
5%
